Genocea Biosciences - GNCA Stock Forecast, Price & News

2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Genocea Biosciences in the last twelve months. There are currently 2 hold ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" GNCA shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in GNCA, but not buy additional shares or sell existing shares.
View GNCA analyst ratings or view top-rated stocks.

2 analysts have issued 1-year price targets for Genocea Biosciences' stock. Their GNCA share price forecasts range from $3.00 to $3.00. On average, they expect the company's share price to reach $3.00 in the next twelve months.
View analysts price targets for GNCA or view top-rated stocks among Wall Street analysts.

Genocea Biosciences, Inc. (NASDAQ:GNCA) posted its quarterly earnings results on Wednesday, October, 27th. The biotechnology company reported ($0.05) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.20) by $0.15. The biotechnology company earned $1.64 million during the quarter. During the same quarter last year, the firm posted ($0.26) earnings per share.

5 employees have rated Genocea Biosciences Chief Executive Officer William Clark on Glassdoor.com. William Clark has an approval rating of 82% among the company's employees.

Based on aggregate information from My MarketBeat watchlists, some companies that other Genocea Biosciences investors own include Hawkins (HWKN), CA (CA), Endologix (ELGX), Chipotle Mexican Grill (CMG), BlackRock (BLK), Aegean Marine Petroleum Network (ANW), Micron Technology (MU), Hudson Technologies (HDSN), Accenture (ACN) and AutoZone (AZO).

Genocea Biosciences trades on the NASDAQ under the ticker symbol "GNCA."

Shares of GNCA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

Genocea Biosciences (NASDAQ:GNCA) has a market capitalization of $0.00 and generates $1.91 million in revenue each year. The biotechnology company earns $-33,200,000.00 in net income (profit) each year or ($0.61) on an earnings per share basis.

Genocea Biosciences' mailing address is 100 ACORN PARK DRIVE, CAMBRIDGE MA, 02140. The official website for the company is www.genocea.com. The biotechnology company can be reached via phone at (617) 876-8191, via email at ir@genocea.com, or via fax at 617-876-8192.